logo
logo

Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio

Mar 18, 2024over 1 year ago

Acquiring Company

Bristol Myers Squibb

Acquired Company

Karuna Therapeutics

LawrencevilleBostonManufacturingHealth CareBiopharmaTherapeuticsBiotechnologyHealth Care

Description

Bristol Myers Squibb has successfully completed the acquisition of Karuna Therapeutics, Inc. This acquisition adds KarXT, an antipsychotic with a novel mechanism of action, and Karuna’s early-stage and pre-clinical pipeline to Bristol Myers Squibb’s portfolio, reinforcing its commitment to strengthening its growth profile in the latter half of the decade and beyond.

Company Information

Company

Bristol Myers Squibb

Location

Lawrenceville, New Jersey, United States

About

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed